Editorial oncologic, endocrine & metabolic: The Current status of tyrosine kinase inhibitors: Do the diarylamine inhibitors of the EGF receptor represent a new beginning?

Expert Opinion on Therapeutic Patents

Volumn 5, Issue 12, 1995, Pages 1245-1257

  Bridges, Alexander J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6 (METHYLAMINO)PYRIDO[3,4 D]PYRIMIDINE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6 N (3,3 DIMETHYLALLYL)ADENINE; AMINOPYRIMIDINE DERIVATIVE; ANILINOQUINAZOLINE DERIVATIVE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; OLOMOUCINE; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; EDITORIAL; HUMAN; NONHUMAN; PATENT; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

EID: 0028788522     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.5.12.1245     Document Type: Editorial

References (48)

1. Signalling by receptor tyrosine kin2ses
2. New insights into protein-tyrosine kinase receptor sig-nalling complexes
3. Jaks and Stats in signalling by the cytokine receptor superfamily
4. Protein tyrosine kinases, with em-phasis on the Src family
5. The role of p21(ras) in receptortyrosine kinase signalling
6. Nuclear protein tyrosine kinases
7. The regulation of tyrosine kinase signalling pathways by growth factor and 6-pro-tein-coupled receptors
8. The emerging role of protein phosphory-lation and cell cycle control in tumour progression
9. EGF re-ceptor in neoplasia and metastasis
10. NELSONJM, SHOWALTER 1-1DII, LEOPOLD WR: Strategies for the discovery of novel tyrosine kinase inhibitors with an-ticancer activity
11. LEVITZK
12. Small molecule inhibitors of tyrosine kinase activity
13. Crystal struc-ture of the catalytic subdomain of cAMP-dependent protein kinase
14. Two structures of the catalytic domain of phosphorylase kinase: an active protein kinase com-plexed with substrate analogue and product
15. Atomic structure of the MAP kinase ERK2 at 2
16. Crystal structure of cyclist-de-pendent kinase-2
17. Crystalstructure of the tyrosine kinase domain of the human Insulin receptor
18. Mechanism of CDK activa-tion revealed by the structure of a cyclinA-CDK2 com-plex
19. Multiple modes of ligand recognition: crystal structures of cyclin-dependent pro-tein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine
20. RADZIO-ANDZELM E: Three protein kinasestructures define a common motif
21. Protein kinases
22. The protein kinasefamily: conserved features and deduced phylogeny of the catalytic domains
23. Epidermal growth factor receptor tyrosine kinase - investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor
24. refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and peptide inhibitor
25. Phosphotransferase and substrate binding mechanism of the cAMP-dependent protein kinase cata-lytic subunit from porcine heart as deduced from the 2
26. Protein kinases 6 - the eukaryoticprotein kinase superfamily: kinase (catalytic) domain structure and classification
27. GOLDSMITHEJ: Activity of the MAP kinase ERK2 is controlled by a flexible surface loop
28. Inhibition of cyclin-dependent kinases lby purine analogues
29. ZILBER-STEIN A: A new series of PDGF receptor tyrosine kinase inhibitors: S-substituted quinoline derivatives
30. A specific inhibitor of the epidermal growth factor recep-tor tyrosine kinase
31. New agents to exploit the EGF receptor family of tyrosine kinases as targets for breast cancer chemotherapy
32. 4,5-Dianilinophthalimide - a protein-ty-rosine kinase inhibitor with selectivity for the epider-mal growth factor receptor signal transduction pathway and potent in vivo antitumor activity
33. Dianilinophthalitnides - potent and selec-tive, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase
34. Tyrosine kinase inhibitors 5
35. Selective inhibition of the platelet-derived growth factor signal transduc-tion pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class
36. Selective inhibition of the tyrosine kinase pp60(src) by analogs of 5,10-d1hydropyrimido[4,5-blquinolin-4(1H)-one
37. Accelerated degra-dation of 160 kDa epidermal growth factor (EGF) recep-tor precursor by the tyrosine kinase inhibitor Herbimycin A in the endoplasmic reticulum of A431 human epidermoid carcinoma cells
38. Depletion of the erb-B2 gene product p185 by benzoquinoid ansamydns
39. Herbimycin A induces the 20 S proteasome-and ubiquitin-dependent degradation of receptor tyro-sine kinases
40. The degree of inhibition of protein tyrosine kinase activity by tyr-phostin 23 and 25 is related to their instability
41. Inhibition of GTP-utilizing enzymes by tyrphostins
42. Inhibi-tion of topoisomerase I activity by tyrphostin deriva-tives, protein kinase blockers: mechanism of action
43. Tyrphostin A617, [(3,5-Di-tert-buty1-4-hydroxybenzylidene)-malononitrile], in-hibits cell growth by disrupting mitochondria